Sign in

CIK 0001674416

  • Large accelerated filer

CRISPR Therapeutics AG

Sign in to watch
Ticker
CRSP
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
Switzerland
Entity type
Operating
EIN
473173478
Phone
+1 617-315-4600
Business address
BAARERSTRASSE 14, ZUG, Switzerland
Former names
CRISPR Therapeutics AG
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$4,881,673
in 7 filings, $1.5M under 10b5-1 plans

Net −$4,881,673. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2017-04-20 Kulkarni Samarth Chief Business Officer Exercise or conversion · Stock Options (Right to Buy) −2,800 311,654
2017-04-20 Dylan-Hyde Tyler Chief Legal Officer Sale −2,937 $17.37 $51K 195,027
2017-04-19 Novak Rodger Chief Executive Officer Exercise or conversion +47,706 $1.81 $86K 1,262,711
2017-04-19 Novak Rodger Chief Executive Officer Sale −32,338 $17.57 $568K 1,230,373
2017-04-19 Novak Rodger Chief Executive Officer Sale −15,368 $18.61 $286K 1,215,005
2017-04-19 Novak Rodger Chief Executive Officer Exercise or conversion · Stock Options (Right to Buy) −47,706 220,387
2017-04-19 Kulkarni Samarth Chief Business Officer Exercise or conversion +7,258 $1.81 $13K 141,305
2017-04-19 Kulkarni Samarth Chief Business Officer Sale −4,809 $17.54 $84K 136,496
2017-04-19 Kulkarni Samarth Chief Business Officer Sale −2,449 $18.54 $45K 134,047
2017-04-19 Kulkarni Samarth Chief Business Officer Exercise or conversion · Stock Options (Right to Buy) −7,258 314,454
2017-04-19 Dylan-Hyde Tyler Chief Legal Officer Sale −4,930 $17.49 $86K 200,274
2017-04-19 Dylan-Hyde Tyler Chief Legal Officer Sale −2,310 $18.58 $43K 197,964
2016-10-24 EMSTER KURT VON Director Conversion +2,354,050 2,354,050
2016-10-24 EMSTER KURT VON Director Conversion +191,764 2,545,814
2016-10-24 EMSTER KURT VON Director Purchase +56,000 $14.00 $784K 2,601,814
2016-10-24 EMSTER KURT VON Director Conversion · Series A-3 Preferred Shares −2,354,050 0
2016-10-24 EMSTER KURT VON Director Conversion · Series B Preferred Shares −191,764 0
2016-10-24 Lundberg Sven Ante Chief Scientific Officer Conversion +55,217 505,217
2016-10-24 Lundberg Sven Ante Chief Scientific Officer Purchase +400 $14.00 $6K 505,617
2016-10-24 Lundberg Sven Ante Chief Scientific Officer Conversion · Series B Preferred Shares −55,217 0

Page 67 of 74 · 1,471 trades